TITLE

Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar

PUB. DATE
February 2012
SOURCE
Biomedical Market Newsletter;2/7/2012, Vol. 21, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on Merck & Co. Inc. announcing the results of the studies performed on Vorapaxar. Vorapaxar is an investigational oral Protease Activated Receptor 1 (PAR 1) thrombin receptor antagonist. It could be used for the prevention of thrombosis, reduction of cardiovascular diseases and clot formation. Study revealed that addition of Vorapaxar to care reduces the risk of heart attack, stroke and cardiovascular death.
ACCESSION #
75133721

 

Related Articles

  • Data from TRACER Study of Vorapaxar, Merck's Investigational Medicine for Cardiovascular Disease, Presented at AHA and Published in NEJM.  // Biomedical Market Newsletter;11/14/2011, Vol. 21, p282 

    The article presents the results of the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) study led by North Carolina's Duke Clinical Research Institute (DCRI). The study is the first clinical trial of vorapaxar from Merck & Co. Inc. for the prevention...

  • Merck gets good news from Vytorin study.  // Caribbean Business;12/23/2010, Vol. 38 Issue 50, p48 

    The article reports that drugmaker Merck & Co. Inc. is bosting a new study showing that its cholesterol-drug Vytorin helps decrease the risk of heart attacks, strokes and the need for heart surgeries in chronic kidney patients by 16%.

  • BIOCHEMICAL AND IN SILICO CLOTTING ACTIVITY OF LATEX FROM ASCLEPIAS CURASSAVICA.L. KARPAGAM, N.; VISWANATHAN, S.; PRABHU, S.; SOMASUNDARAM, SULOCHANA; SIVANANDHAM, M. // International Journal of Pharma & Bio Sciences;Oct-Dec2013, Vol. 4 Issue 4, pB-542 

    The crude latex extract of Asclepias curassavica contains many proteins and exhibits strong proteolytic activity. The study was done to identify the clotting factor present in the latex of Asclepias curassavica and to analyze the thrombin like activity of the clotting factor. In this study the...

  • Merck's entry in sleep aids tug-of-war. Weinstein, Deborah // Medical Marketing & Media;Mar2012, Vol. 47 Issue 3, p11 

    The article reports on the results of Merck & Co. Inc.'s Phase III drug suvorexant in the U.S. in 2012 and notes that it focuses on orexin receptors.

  • Merck Highlights the Progress Made by Januvia.  // Chain Drug Review;9/28/2015, Vol. 37 Issue 15, p112 

    The article reports on the progress on drug company Merck & Co.'s drug trial of Januvia for the management of diabetes.

  • Amgen, Merck target cancer. Investor's Business Daily // Investors Business Daily;12/7/2015, pA02 

    The article reports on the announcement made by biotechnology company Amgen regarding its partnership with pharmaceutical company Merck on a study, which combines Merck's Keytruda drug with Amgen's leukemia drug Blincyto.

  • Merck Sticks to Its Guns.  // Drug Discovery & Development;Apr2002, Vol. 5 Issue 4, p22 

    Reports the development of strong internal research program for creating breakthrough medications by Merck & Co. in the U.S. Increase of the expenditure Research & Development; Development of AIDS vaccine; Assistance of the company clinical trials.

  • GTx, Merck in $500M Deal For Muscle-Loss Drugs.  // Bioworld Week;11/12/2007, Vol. 15 Issue 46, p3 

    The article reports on the partnership between GTx Inc. and Merck and Co. Inc. to develop and commercialize selective androgen receptor modulators (SARMs), a class of drugs used to target musculoskeletal conditions in the U.S. It states that the agreement calls for Merck to cover all future...

  • What They're Saying . . .  // Pharmaceutical Executive;Aug2005, Vol. 25 Issue 8, p19 

    Presents a statement by Kent Jarrell, spokesman for Merck & Co. Inc., regarding the reasons why the company canceled the research about Vioxx's effect on the heart in 2002.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics